Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66(Suppl III):iii2-22

This article mistakenly identifies all three anti-TNF agents (adalimumab, etanercept and infliximab) as having approval for the indication of juvenile idiopathic arthritis of the polyarticular type. Currently only etanercept holds this indication. The cited references to support the statement (refs 60-62) are all publications concerning etanercept.